The pharmaceutical industry, like other industries, has been struggling with the challenges caused by the new realities for more than a year. Some foreign companies have left the Russian pharmaceutical market, and the supply of certain drugs from abroad is subject to interruptions. As a result, Russians who were frequent users of imported medicines are now experiencing difficulties in obtaining the drugs they need.

Due to the new geopolitical situation, one of the priorities of state policy in regulating the circulation of medical drugs is to promote the domestic production of medicines, primarily from the list of essential medicines and medicines of strategic importance. Participants in the industry are tasked with the important goal of ensuring Russia’s pharmaceutical sovereignty at all stages of production, starting from intermediates used for the production of pharmaceuticals, and ending with the full-scale import substitution of medicines based on new developments.

It is obvious that today efforts need to be focused not only on developing a roadmap for achieving sustainable national sovereignty in relation to technology, but also on strengthening the country’s export potential and increasing the share of competitive original Russian-developed drugs on international markets. During the session, experts will discuss:

• What are the barriers to achieving technological sovereignty in the pharmaceutical industry?
• Is supply from Russian companies enough to keep up with demand?
• What role do state corporations and large holdings play in developing the production of materials, components, and raw materials?
• What incentives on the part of the state can make it easier to achieve sovereignty within the timeframe required, given the sanctions?
• What steps can be taken to increase the market supply of innovative drugs and strengthen the export potential of the Russian pharmaceutical industry, under the current conditions?